| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9108973 | TAIHO ONCOLOGY | 3,5-disubstituted alkynylbenzene compound and salt thereof |
Feb, 2033
(9 years from now) | |
| US10434103 | TAIHO ONCOLOGY | Crystal of 3,5-disubstituted benzene alkynyl compound |
Mar, 2036
(12 years from now) | |
Lytgobi is owned by Taiho Oncology.
Lytgobi contains Futibatinib.
Lytgobi has a total of 2 drug patents out of which 0 drug patents have expired.
Lytgobi was authorised for market use on 30 September, 2022.
Lytgobi is available in tablet;oral dosage forms.
Lytgobi can be used as method of treating intrahepatic cholangiocarcinoma.
Drug patent challenges can be filed against Lytgobi from 2026-09-30.
The generics of Lytgobi are possible to be released after 31 March, 2036.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Sep 30, 2027 |
| Orphan Drug Exclusivity (ODE) | Sep 30, 2029 |
Drugs and Companies using FUTIBATINIB ingredient
NCE-1 date: 2026-09-30
Market Authorisation Date: 30 September, 2022
Treatment: Method of treating intrahepatic cholangiocarcinoma
Dosage: TABLET;ORAL
LYTGOBI family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic